Corticotropin releasing factor (CRF) is a neuropeptide that plays a key role in behavioral and physiological responses to stress. A large body of animal literature implicates CRF acting at type 1 CRF receptors (CRFR1) in consumption by alcohol-dependent subjects, stress-induced reinstatement of alcohol seeking, and possibly binge alcohol consumption. These studies have encouraged recent pilot studies of CRFR1 antagonists in humans with alcohol use disorder (AUD). It was a great disappointment to many in the field that these studies failed to show an effect of these compounds on stressinduced alcohol craving. Here, we examine these studies to explore potential limitations and discuss preclinical and human literature to ask whether CRFR1 is still a valid drug target to pursue for the treatment of AUD.
M ISUSE OF ALCOHOLIC beverages is a major public health problem that incurs a huge annual economic cost estimated at nearly $235 billion in the United States (Rehm et al., 2009) . Alcohol use disorder (AUD) is very common, with a 12-month prevalence of 13.9% and lifetime prevalence of 29.1% . Treatment options are limited to psychosocial intervention, 3 Federal Drug Administration (FDA)-approved medications (disulfiram, acamprosate, and naltrexone), and a handful of drugs approved for other indications, all with relatively small effect sizes (Franck and Jayaram-Lindstr€ om, 2013; Johnson, 2008) . There is a clear need for additional treatments based on a deeper understanding of the neurobiological mechanisms that underlie AUD.
A large body of preclinical work supports the conclusion that alcohol-induced neuroadaptations in brain stress response mechanisms involving corticotropin releasing factor (CRF) promote excessive alcohol intake. CRF is a 41-amino acid peptide encoded by the Crh gene and was originally identified as a major regulator of the endocrine stress response (Vale et al., 1981) . CRF and the related peptides urocortin 1 (UCN1), urocortin 2 (UCN2), and urocortin 3 (UCN3) have emerged as key regulators of behavioral, cognitive, neuroendocrine, autonomic, and immunologic responses to stress (Bale and Vale, 2004; Binder and Nemeroff, 2010; Koob, 2009) . These peptides produce their effects by activating 2 class B subtype G protein-coupled receptors coupled to G S : CRF receptor type 1 (CRFR1) encoded by the CRHR1 gene and CRF receptor type 2 (CRFR2), encoded by the CRHR2 gene.
Numerous animal studies have identified CRFR1 as a major driver of dependence-based alcohol consumption in rodents. We do not review this extensive literature here but instead call attention to several excellent reviews Heilig and Koob, 2007; Henckens et al., 2016; Mantsch et al., 2016; Phillips et al., 2015; Shalev et al., 2010; Spanagel et al., 2014; Zorrilla et al., 2013) . In humans, genetic studies have identified an association between CRFR1 polymorphisms and risk of AUD in some populations (Blomeyer et al., 2008; Glaser et al., 2014; Ray et al., 2013; Ribbe et al., 2011; Schmid et al., 2010; Treutlein et al., 2006) . Such findings have prompted recent efforts to test CRFR1 antagonists in humans as potential treatments for AUD (Kwako et al., 2015b; Schwandt et al., 2016) . Unfortunately, these studies yielded negative findings. Here, we review the design of these trials and its basis in the prior literature, the pharmacology of the tested compounds, our knowledge about differences between human and rodent CRF systems, and clues to other neuropeptide systems that might compensate or override CRFR1 in regulating human drinking.
MATERIALS AND METHODS
We identified preclinical and human clinical studies through queries of PubMed and the ClinicalTrials.gov databases. The initial PubMed search was undertaken using the following terms: (alcohol; OR ethanol [EtOH] ) AND (corticotropin releasing hormone; OR corticotropin releasing factor) AND antagonist AND (drinking; OR intake; self-administration; consumption; preference). This search yielded 42 articles. We excluded reviews and non drinking studies and were left with 32 papers for detailed review. We added additional papers from searches for specific drugs and reinstatement of alcohol seeking and for rodent and primate neuroanatomy of CRF and CRFRs. We used the PubMed tools for finding similar articles and citing articles to expand our searches. We also checked recent reviews on the CRF system, AUD medication development, and AUD genetics to identify papers we had missed. Finally, we searched ClinicalTrials.gov using the term "alcohol" and the specific drug in which we were interested. In all, we reviewed 192 manuscripts and 10 studies on ClinicalTrials.gov that are actively recruiting participants.
RESULTS

Summary of CRFR1 Antagonist Trials in AUD
There are 2 published double-blind, placebo-controlled (DBPC) trials conducted by the same investigators on treatment-seeking, anxious individuals with AUD (Kwako et al., 2015b; Schwandt et al., 2016 ) that tested whether the CRFR1 antagonists pexacerfont or verucerfont reduce stress-induced craving for alcohol. Participants were admitted to the National Institutes of Health (NIH) Clinical Center where they first underwent managed alcohol withdrawal before entering the study, which was performed in the hospital.
The pexacerfont study recruited 55 participants based on estimates of effect size and power, but the verucerfont study was stopped after recruitment of 44 participants because of adverse events, restricted drug availability, and negative results in the earlier pexacerfont trial, which prompted a futility analysis that indicated a low probability of finding an effect on the primary measure of craving. Almost all subjects (49 of 55) in the pexacerfont study were men, whereas the verucerfont study was conducted only with women due to an inhibitory effect of verucerfont on sperm production and evidence of damage to seminiferous epithelium in animals (Dunlop et al., 2014) .
In both studies, subjects underwent 2 behavioral challenge sessions. The first consisted of a Trier Social Stress Test combined with an alcohol cue challenge during which they smelled and manipulated an alcohol stimulus (Trier-CR). The second consisted of personalized auditory guided imagery scripts, during which subjects were presented stress-associated, alcohol cue-associated, or neutral stimuli. Craving in both sessions was rated using the Alcohol Urge Questionnaire (AUQ) (Bohn et al., 1995) , while anxiety and emotional responses were measured by the Spielberger State Trait Anxiety Inventory-State Version (STAI) (Spielberger et al., 1970) and the Subjective Units of Distress Scale (SUDS) (Wolpe, 1982) . Cortisol and ACTH levels were used to measure hypothalamic-pituitary-adrenal (HPA) axis responses. Control experiments for drug bioavailability included plasma and cerebrospinal fluid (CSF) concentrations for pexacerfont, HPA responses in a dexamethasone-CRF test for verucerfont, and brain functional magnetic resonance imaging (fMRI) responses to stressful stimuli for both drugs.
Pexacerfont had no significant effect on craving and stress measures, increases in cortisol or ACTH evoked during the Trier/CR procedure, or fMRI blood oxygenation level dependent (BOLD) responses to fearful faces, despite measurable levels of the drug in blood and CSF that were predicted to provide~90% central CRFR1 occupancy. In contrast, verucerfont suppressed CRF-evoked rises in ACTH and cortisol in the dexamethasone-CRF test, and fMRI BOLD responses to fearful faces, but did not reduce stress-or alcohol cue-evoked craving.
Pharmacology
A particularly surprising finding in the pexacerfont study was the mismatch between predicted target engagement and lack of drug effect on behavioral and endocrine measures. This was postulated to have been due to its rapid dissociation rate from CRFR1 (Fleck et al., 2012) which prompted assessment of drug effects on the HPA axis of rats in the verucerfont study. There it was found that CRFR1 antagonists with a slower off-rate (verucerfont and R121919) suppressed the rat HPA axis, while those with a faster off-rate (pexacerfont and CP-316,311) were ineffective. Target engagement was confirmed in the verucerfont study by demonstrating its effect in the dexamethasone-CRF test. One caveat is that this test is a mixed measure of pituitary and hypothalamic CRFR1 responses, and as the pituitary is outside the blood-brain barrier, the test is not a selective measure of central nervous system (CNS) target engagement. However, verucerfont reduced the fMRI BOLD response in the right amygdala to fearful faces, suggesting that it was effective centrally. Surprisingly however, verucerfont did not reduce anxiety measured by the STAI following either emotional challenge. In fact, subjects that received verucerfont reported modestly higher anxiety ratings on the STAI than subjects that received placebo just before and during the Trier/Cue reactivity test, although not before or during stress imagery sessions. Consistent with such results, Grillon and colleagues (2015) recently examined the effect of verucerfont on anxiety-and fear-potentiated startle in healthy female volunteers by measuring the magnitude of the eyeblink response to bursts of white noise presented during 120-second trials in which subjects experienced 6 brief (8 seconds) presentations of a unique visual cue that signified the delivery of a predictable or unpredictable shock, or no shock at all (Schmitz and Grillon, 2012) . Despite significant preclinical work describing anxiolytic actions of CRFR1 antagonists, verucerfont had no effect on anxiety-potentiated startle. These results call into question the efficacy of CRFR1 antagonism in humans as a means of reducing negatively reinforcing stimuli, although it is possible that CRFR1 antagonists would have been anxiolytic on a different test, in subjects with chronic anxiety, in males, or at a different dose.
Only females were recruited for the verucerfont study, yet almost all animal studies with CRFR1 antagonists have been performed with male animals. A large preclinical literature suggests the potential for differences in behavioral responses to alcohol across sexes (Becker and Koob, 2016) . Only females were recruited because verucerfont produced testicular toxicity in animals (Dunlop et al., 2014) . It is not known if this is a general property of CRFR1 antagonists or is unique to verucerfont. CRFR1 is expressed by Leydig cells of the testes where it has been found to stimulate (Huang et al., 1995; McDowell et al., 2012) or inhibit (Rivier, 2008; Rossi et al., 2012) Leydig cell steroidogenesis. Given these conflicting findings, it will be important for future drug discovery efforts to determine whether impairment of testicular function is a property common to all CRFR1 antagonists.
Treatment Approaches and the Addiction Cycle
In discussing treatment approaches, we found useful the framework proposed by Koob and Le Moal (Koob, 2008; Koob and Le Moal, 1997) by which addictive disorders are conceptualized as having 3 phases: (i) a binge/intoxication phase in which the rewarding effects of alcohol are experienced, (ii) a withdrawal/negative affect phase with dysphoric emotional symptoms such as anxiety and distressing physical withdrawal signs that are negatively reinforcing, and (iii) a preoccupation/anticipation phase characterized by craving and susceptibility to relapse (Fig. 1) . These phases are postulated to interact in a cycle that intensifies with repeated alcohol use. Experimental procedures in animals that model these phases include: alcohol self-administration and conditioned place preference (binge/intoxication phase); anxietylike behaviors, conditioned place aversion, withdrawalinduced increases in alcohol self-administration, and elevated reward thresholds (withdrawal/negative affect phase); drug-, stress-, or cue-induced reinstatement of drug seeking (preoccupation/anticipation phase) (Koob and Mason, 2016) . Approaches to treating AUD have targeted different phases of this cycle by diminishing rewarding or intensifying aversive effects of alcohol (binge/intoxication phase); reducing the negatively reinforcing effects of withdrawal (withdrawal/ negative affect phase); or decreasing craving that leads to relapse (preoccupation/anticipation phase). It has been particularly difficult to develop medications that interfere with craving that characterizes the preoccupation/anticipation phase. Below we discuss preclinical studies that focus on CRFR1 involvement in aspects of these phases of AUD.
Development of the Stress-Induced Reinstatement and Craving Paradigm
The pexacerfont and verucerfont studies were designed to test the effect of CRFR1 antagonists on craving, and were based on preclinical evidence demonstrating a prominent role for CRFR1 in stress reactivity and stress-induced reinstatement of drug seeking in alcohol-dependent animals. CRF signaling is up-regulated in the extended amygdala of alcohol-dependent animals (Merlo Pich et al., 1995; Olive et al., 2002) , and this up-regulation is thought to underlie heightened stress reactivity associated with alcohol dependence Cole et al., 1990; Valdez et al., 2003; Wills et al., 2010) . Consistent with this conclusion, CRFR antagonists reduce stress-induced reinstatement of alcohol seeking in rodents evoked by footshock or administration of the anxiogenic a2 adrenergic receptor antagonist yohimbine (Gehlert et al., 2007; Hansson et al., 2006; Lê et al., 2000 Lê et al., , 2013 Liu and Weiss, 2002; Marinelli et al., 2007) . Cue-and stress-induced reinstatement of drug seeking are established models of evoked drug craving in animals Shaham et al., 2003) , and stress-induced craving in human laboratory settings predict subsequent relapse (Cooney et al., 1997; Higley et al., 2011; Sinha et al., 2011a) . These findings have informed a translational approach that targets the preoccupation/anticipation stage of the addiction cycle. In this paradigm, drugs that inhibit stress-induced reinstatement in rodents are tested for their ability to reduce stress-induced craving in humans before initiating a larger and more expensive clinical trial of alcohol consumption (Higley et al., 2012; Sinha et al., 2011b) . This paradigm informed the pexacerfont and verucerfont trials, which evolved from animal studies demonstrating that CRFR1 antagonists block stress-induced reinstatement, and which were designed with stress-induced alcohol craving as the primary behavioral outcome measure.
There are several limitations to this paradigm that warrant consideration. First, in reinstatement experiments, animals are tested for their attempts to obtain alcohol, not for their actual consumption of alcohol; for yohimbine, reinstatement of alcohol seeking and alcohol intake appear to involve different brain circuits that are differentially sensitive to CRFR antagonism (Lê et al., 2013) . Second, self-administration is extinguished in animals through repeated sessions of non reinforced operant responding, which is a situation that almost never occurs in humans. Recent studies have begun to explore choice-based "voluntary abstinence" approaches (Caprioli et al., 2017) . Third, as the CRFR antagonist D-Phe-CRF did not reduce alcohol cue-induced reinstatement of seeking in rodents (Liu and Weiss, 2002) , CRFR1 antagonists were unlikely to limit craving induced by the alcohol cues used in the recent human laboratory studies. Finally, the data presented in the pexacerfont and verucerfont trials (Kwako et al., 2015b; Schwandt et al., 2016) indicate that the guided imagery scripts do not engage the HPA axis under the conditions used in these studies.
Promising AUD Medications that Decrease Stress-Induced Reinstatement and Craving
Stress-induced reinstatement of alcohol seeking in rodents is a promising approach for medications development in AUD as several drugs that decrease reinstatement have been effective in reducing drinking in some human subjects. For example, the 5-HT 3 receptor antagonist ondansetron reduced footshock stress-induced reinstatement of alcohol seeking in Wistar rats (Lê et al., 2006) . In a DBPC study of 71 male, treatment-seeking, non abstinent alcoholics, ondansetron reduced alcohol consumption, but only when the heaviest drinkers were removed from the analysis (Sellers et al., 1994) . In 2 related DBPC studies, ondansetron reduced craving (Johnson et al., 2002) and alcohol consumption (Johnson et al., 2000) in subjects with early onset, but not late onset, alcoholism. A similar decrease in drinking was observed in early onset alcoholics in a subsequent open label trial .
Another example is the a1 adrenergic receptor antagonist prazosin, which reduced stress-induced reinstatement of alcohol seeking evoked by yohimbine or footshock in Wistar rats (Lê et al., 2011) , and reduced increases in drinking evoked by the stress of alcohol deprivation in P rats selected for high alcohol preference (Froehlich et al., 2015) . In an inpatient laboratory study of 17 treatment-seeking, alcohol-dependent men and women tested with guided imagery scripts after 3 weeks of hospitalization, craving scores following stress imagery declined over 60 minutes of testing more rapidly in prazosin-treated than placebo-treated subjects (Fox et al., 2012) . In 1 outpatient, DBPC pilot study of 17 men with alcohol dependence, prazosin dramatically reduced the number of drinks consumed by 88% and the number of drinking days by 84% during the final 3 weeks of the 6-week study (Simpson et al., 2009 ). This finding was confirmed in a second outpatient pilot study by the same group that involved 20 men and women with alcohol dependence and posttraumatic stress disorder (PTSD), although 6 in the prazosin group required dose reductions for side effects (Simpson et al., 2015) . However, a more extensive, outpatient, DBPC trial of 96 veterans with alcohol dependence and PTSD found no significant effect of prazosin over placebo on drinking measures during 13 weeks of treatment (Petrakis et al., 2016) . This negative result somewhat dampens enthusiasm for prazosin as an effective treatment for stress-related drinking. Currently, there are 3 clinical trials testing prazosin in AUD. One is recruiting 120 outpatient subjects for a 12-week, randomized, DBPC study of the effects of prazosin on alcohol and cocaine use and craving in treatment-seeking individuals with AUD (ClinicalTrials.gov: NCT00585780). A second outpatient trial is recruiting 300 active duty returnees from Iraq or Afghanistan with AUD with or without PTSD to study the effect of prazosin on self-reported alcohol craving and alcohol use over 13 weeks (ClinicalTrials.gov: NCT02226367). A third study is recruiting 120 veterans with AUD to investigate the effect of outpatient treatment with prazosin alone or combined with naltrexone on consumption and on craving measured at the end of 7 weeks in the laboratory (ClinicalTrials.gov: NCT02322047).
The glucocorticoid receptor antagonist mifepristone is a promising therapeutic, which when administered systemically or locally into the central amygdala (CeA), reduced yohimbine stress-induced reinstatement of EtOH seeking in male Long-Evans rats (Simms et al., 2012) and when given systemically reduced alcohol self-administration in alcohol-dependent Wistar rats (Vendruscolo et al., 2015) . In a recent study, mifepristone reduced alcohol-cued craving and self-reported alcohol consumption in 56 alcohol-dependent, outpatient human volunteers who had been abstinent for 3 days before the alcohol cue laboratory session (Vendruscolo et al., 2015) . Mifepristone effects on stress-induced craving are not yet known, but a pilot study is currently recruiting participants to examine its effect on yohimbine-induced craving (ClinicalTrials.gov: NCT02243709). A much larger clinical trial is recruiting 150 outpatient subjects for an 8-week, randomized, DBPC, dose-ranging study of the effects of mifepristone (0, 600, 1,200 mg/d) on drinking and craving (ClinicalTrials.gov: NCT02179749), and another is recruiting 150 inpatient detoxified subjects with AUD to test effects of mifepristone on fMRI measures, alcohol motivated responses, and subjective responses to alcohol (ClinicalTrials.gov: NCT02989662).
There has been recent interest in a2 adrenergic receptor agonists as AUD medications. Lofexidine reduced footshock stress-induced reinstatement (Lê et al., 2005) , and guanfacine reduced yohimbine-induced reinstatement (Lê et al., 2011) of alcohol seeking in Wistar rats. In a recent inpatient human laboratory study of 40 cocaine-dependent men and women who also abused alcohol, guanfacine reduced alcohol craving reported during stress or cocaine cue guided imagery sessions in female, but not in male subjects (Fox et al., 2014) . Two trials evaluating the effect of guanfacine on stress-induced drinking (ClinicalTrials.gov: NCT02164422) and on relapse risk among women with AUD (ClinicalTrials.gov: NCT03137082) are currently recruiting subjects.
Another drug target of interest is the neurokinin-1 (NK1) receptor. In rats, the NK1 receptor antagonist L822429 reduced footshock stress-induced reinstatement of alcohol seeking (Schank et al., 2011) , and in humans the NK1 receptor antagonist tradipitant (LY686017) reduced alcohol craving evoked by the Trier-CR test in an inpatient, DBPC study of 50 detoxified alcohol-dependent subjects (George et al., 2008) . However, in a more recent study of 53 subjects with PTSD and alcohol dependence, the NK1 receptor antagonist aprepitant did not reduce craving evoked by stressful guided imagery scripts (Kwako et al., 2015a) . A trial of aprepitant in comorbid alcohol and marijuana dependence has recently been completed, but results have not yet been reported (ClinicalTrials.gov NCT02210195). There are currently no other ongoing registered trials of NK1 antagonists in AUD.
While stress-induced reinstatement and craving shows promise as a paradigm for AUD drug development, it is important to note that some treatments for AUD have been developed through other approaches. Gabapentin has not been studied for effects on reinstatement of alcohol seeking in animals, but in a human laboratory study of 33 non-treatment-seeking, alcohol-dependent volunteers, it reduced alcohol craving elicited by affective images followed by beverage cues (Mason et al., 2009) . Small randomized clinical trials have found gabapentin to delay the onset of heavy drinking (Brower et al., 2008) , decrease the number of drinks per day and percentage of heavy drinking days (Furieri and Nakamura-Palacios, 2007) , and improve abstinence and rates of no heavy drinking (Mason et al., 2014) . As a result, the National Institute on Alcohol Abuse and Alcoholism is currently conducting a multisite DBPC trial of an extendedrelease form of gabapentin in patients with AUD (ClinicalTrials.gov: NCT02252536).
Another example is topiramate, which suppresses drinking in patients with AUD (Baltieri et al., 2008; Blodgett et al., 2014; Johnson et al., 2003; Kranzler et al., 2014; Rubio et al., 2004) , but has never been tested for effects on stress-induced reinstatement of alcohol seeking in animals. It failed to suppress craving in 1 human laboratory study (Miranda et al., 2008) , though in a recent study by the same group, it reduced craving only while participants were drinking, suggesting that it reduces drinking by blunting alcohol-induced craving (Miranda et al., 2016) . However, a recent DBPC trial of topiramate in 30 veterans with comorbid PTSD and AUD found it to be effective in reducing alcohol craving and drinking and in reducing PTSD symptom severity (Batki et al., 2014) , suggesting that it can suppress stress-related drinking.
A third example is varenicline, which is a partial agonist at a4b2 nicotinic acetylcholine receptors that is an effective FDA-approved smoking cessation aid (Cahill et al., 2016) . It has recently gained attention as a treatment for AUD. Varenicline was never tested for effects on stress-induced reinstatement, but it inhibited cue-induced reinstatement of alcohol seeking in Wistar rats Wouda et al., 2011) and cue-induced alcohol seeking in baboons (Kaminski and Weerts, 2014) . It has also reduced alcohol self-administration in animals (Bito-Onon et al., 2011; Hendrickson et al., 2010; Kaminski and Weerts, 2014; Sotomayor-Z arate et al., 2013; Steensland et al., 2007; Wouda et al., 2011) and decreased drinking and alcohol craving in human smokers and non smokers (Fucito et al., 2011; Litten et al., 2013; McKee et al., 2009; Mitchell et al., 2012; Plebani et al., 2013; Roberts et al., 2017; Schacht et al., 2014) .
In summary, mounting evidence suggests that stressinduced reinstatement and craving are valuable tools for early AUD drug development, and have heuristic value for predicting drug efficacy in clinical trials. However, the most effective FDA-approved AUD medication with a CNS mechanism of action, naltrexone, is ineffective in reducing stress-induced reinstatement of alcohol seeking (Lê et al., 1999) and acamprosate, the other approved CNS active medication, has not been tested against stress-induced reinstatement of alcohol seeking, although it failed to suppress footshock-induced heroin seeking (Spanagel et al., 1998) . Taken together with studies of gabapentin, topiramate, and varenicline noted above, we conclude that a negative result in tests of stress-induced reinstatement and craving should not eliminate a candidate therapeutic from further development if there is evidence of a beneficial effect on phases of the addiction cycle besides the preoccupation/anticipation phase.
CRF and the Withdrawal/Negative Affect Phase
Several animal studies predict a role for CRF in the withdrawal/negative affect phase of the addiction cycle. CRFR1 antagonists, administered systemically or directly into the amygdala, reduce drinking and withdrawal-induced anxiety in alcohol-dependent animals (Chu et al., 2007; Funk et al., 2006 Huang et al., 2010; Knapp et al., 2011; Overstreet et al., 2004; Rassnick et al., 1993; Valdez et al., 2002; Wills et al., 2010) . CRFR1 antagonists also reduce somatic and emotional signs of acute withdrawal (Finn et al., 2007; Overstreet et al., 2004; Rassnick et al., 1993; Valdez et al., 2002; Wills et al., 2009 Wills et al., , 2010 . These findings suggest that administration during early abstinence could minimize the negative reinforcing effects of early abstinence.
Current clinical evidence supports the concept of craving subtypes, with reward craving provoked by positive states in which alcohol acts as a positive reinforcer versus relief craving in which alcohol acts as a negative reinforcer against negative symptoms of withdrawal (Gl€ ockner-Rist et al., 2013). In the pexacerfont and verucerfont studies, subjects were enrolled in a standard NIH treatment program for alcohol dependence and entered the studies once medical management of withdrawal, if needed, had been completed. In contrast, human laboratory studies of gabapentin and mifepristone were performed in non-treatment-seeking outpatients with AUD who were abstinent for only 3 days (Mason et al., 2009; Vendruscolo et al., 2015) . To provoke craving, subjects were shown affective images and provided a preferred alcoholic beverage to see and smell, but not consume. Both drugs reduced craving, and in subsequent human trials, they reduced alcohol intake (Mason et al., 2014; Vendruscolo et al., 2015) . Although highly supported by preclinical data, administration of CRFR1 antagonists during early abstinence, when relief craving is likely to be strongest, has not yet been tested in humans.
CRF and the Binge/Intoxication Phase
In addition to reducing negatively reinforced drinking in dependent animals, systemic (Lowery et al., 2010; LoweryGionta et al., 2012; Sparta et al., 2008) or intra-CeA (Lowery-Gionta et al., 2012) blockade of CRFR1, or systemic knockout of CRFR1 or CRF (Kaur et al., 2012 ) reduced alcohol but not sucrose intake in mice in the drinking in the dark (DID) procedure, which was developed as a model of binge drinking (Rhodes et al., 2005; Thiele, 2012) . Similarly, alcohol consumption in the DID procedure was reduced by administration of a CRFR1 antagonist into the ventral tegmental area (Rinker et al., 2016; Sparta et al., 2013) , which is a brain region important for the reinforcing effects of abused drugs including alcohol (Gonzales et al., 2004) . Taken together, these findings suggest that CRFR1 may mediate rewarding effects of alcohol and contribute to the binge/intoxication stage, providing a rationale for human clinical trials designed to test whether CRFR1 antagonists reduce binge drinking. Of note, in 1 study that used a 2-bottle choice DID procedure, CRFR1 antagonists also suppressed water intake, as well as food consumption (Giardino and Ryabinin, 2013) , suggesting that the effect of CRFR1 antagonists on consummatory behavior is not specific for EtOH. However, naltrexone, which reduces alcohol consumption in humans, can also reduce water and food intake in animals (Blasio et al., 2014; Simms et al., 2008) , indicating that such findings should not necessarily discourage further testing of CRFR1 antagonists in humans.
Comparative Anatomy of the CRF System
The degree to which the CRF system differs across species is likely very important for making predictions about the efficacy of CRFR1 antagonists in humans based on animal studies. The distribution of CRFR1 in rat and mouse brain is similar (Radulovic et al., 1998; Van Pett et al., 2000) , but the distribution of CRF-secreting neurons is not. Both species contain many CRF neurons in the paraventricular nucleus of the hypothalamus (PVN), CeA, and bed nucleus of the stria terminalis (BNST), but extended amygdala CRF neurons exhibit anatomical differences. CRF neurons in mouse CeA are found anteriorly, whereas in rat they cluster in the posterior portion of the CeA (Asan et al., 2005; Pomrenze et al., 2015; Sanford et al., 2017) . The lateral capsular subregion of the CeA, which contains serotonergic inputs in both species, has a dense CRF fiber plexus in mice that is absent in rats, providing an anatomical basis for interspecies differences in CRF-serotonergic interactions in the CeA (Asan et al., 2005) . In addition, CRF neurons in the mouse dorsal BNST are widely distributed and lie outside of the oval nucleus, whereas in rat they cluster in the oval nucleus (Nguyen et al., 2016; Pomrenze et al., 2015) . Adding to the anatomical differences, there is evidence that BNST CRF neurons have different morphological and electrophysiological properties when compared in rat, mouse, and non human primates (Daniel et al., 2017) . Additional differences include much greater abundance of CRF neurons in the medial preoptic area of rats compared with mice, greater numbers of CRF neurons in the lateral septal and lateral parabrachial nuclei in mice compared with rats, and presence of CRF neurons in the dorsal motor nucleus of the vagus only in mice .
The anatomy of the CRF system in non human primates provides additional evidence for interspecies differences. In Macaca mulatta (Sanchez et al., 1999) and Macaca fascicularis (Millan et al., 1986) , CRFR1, as assessed by in situ hybridization and radioligand binding, is widespread in a distribution that is similar to rat brain, with notable exceptions. For example, in the rat amygdala, CRFR1 is mainly outside of the CeA, whereas in Macaca mulatta there are modest levels in the central nucleus together with the highest amygdala levels of CRFR2 (Sanchez et al., 1999) . In addition, levels of CRFR1 receptor binding and mRNA within the locus coeruleus of M. mulatta were much higher than in the rat brainstem.
Interspecies differences have also been found in the distribution of CRF neurons in monkey and rat brain. In M. fascicularis and Saimiri sciureus, CRF immunoreactive neurons and fibers are found in a distribution generally similar to rats. However, unlike rats, there were no CRF neurons outside of the PVN in the primate hypothalamus, but there were CRF neurons in thalamic intralaminar nuclei and midbrain tegmentum, with terminal fibers in the lateral substantia nigra pars compacta, the interpeduncular nucleus, and parasagittal cerebellar cortex (Foote and Cha, 1988) . In the S. sciureus amygdala, the distribution of CRF neurons is quite different from the rat, with most CRF perikarya present in basal and lateral nuclei instead of in the CeA, and high densities of CRF fibers and terminals in lateral and cortical nuclei (Bassett and Foote, 1992) .
A striking finding in our search of the anatomical literature was the paucity of information about the human CRF system. Two studies have examined the human brainstem and found a dense network of CRF fibers in the locus coeruleus similar to nonhuman primates, and more extensive than in rodents (Austin et al., 1995; Pammer, 1990) . One (Austin et al., 1995) reported a continuous population of CRF neurons that extend from the pedunculopontine tegmental nucleus to the ventral lateral dorsal tegmental region, similar to what was observed in nonhuman primates (Foote and Cha, 1988) . These results suggest a potentially more important role for brainstem CRF and CRF-adrenergic interactions in human than in the rodent stress responses. A study of the human amygdala found CRF cell bodies and fibers mainly in the lateral and basal nuclei, similar to nonhuman primates (Powers et al., 1987) . These nuclei have substantial connections with the neocortex, suggesting that amygdala CRF neurons are more likely to influence neocortical function in primates than in rodents. Such interspecies differences could impact behavior and influence species-specific differences in response to CRFR antagonists. More studies of the CRF system in the human extended amygdala, particularly relative to other species, could help shed further light on this possibility and increase our ability to translate preclinical studies of this peptide system.
CRF as 1 Component of a Stress Signaling Network
In addition to CRF, several other neurotransmitter systems contribute to the negative emotional state associated with alcohol dependence (Koob, 2008) . These include, but are not limited to, pro-arousal and stress neuropeptides dynorphin, orexin, and vasopressin, and anti stress peptides nociceptin and neuropeptide Y (NPY). AUD phenotypes most likely depend on the relative balance between these systems, and interspecies differences in this balance may contribute to the low efficacy of CRFR1 antagonists in humans. We discuss here 2 neuropeptides for which much is known in relation to preclinical models of alcohol dependence-dynorphin and NPY.
Dynorphin is an opioid neuropeptide that binds the kappa opioid receptor (KOR) (Chavkin et al., 1982) and is important for aversive responses in rodents and humans (Koob, 2008; Land et al., 2008; Shippenberg et al., 2007) . Numerous studies indicate a role for the KOR system in alcohol seeking (Anderson and Becker, 2017) . Of particular note, in nonalcohol-dependent Long-Evans rats, the KOR agonist U50,488 reinstated alcohol seeking while the KOR antagonist nor-BNI blocked U50,488-induced, yohimbine stressinduced, and alcohol cue-induced reinstatement of alcohol seeking (Funk et al., 2014) . Interestingly in this study, the CRFR1 antagonist antalarmin also inhibited U50,488-induced reinstatement of alcohol seeking, indicating an interaction between KOR and CRFR1. Consistent with a role in negative affect, dynorphin signaling in the extended amygdala also promotes anxiety-like behavior (Crowley et al., 2016) . This also appears to involve an interaction with CRF, as anxiety produced by CRF injections into the lateral ventricles was absent in prodynorphin knockout mice or in mice pretreated with nor-BNI (Bruchas et al., 2009; Land et al., 2008) . Supporting an interaction between CRF and dynorphin, roughly 60 to 75% of CRF neurons in the rat and mouse CeA co-express dynorphin (Kim et al., 2017; Marchant et al., 2007; Pomrenze et al., 2015) . Nothing is known about this interaction in primates. If extensive and important, then combining CRFR1 and KOR antagonists may be necessary to diminish stress-induced craving in humans.
NPY is a 36 amino acid neuropeptide that is abundant and widely distributed in the brain and reduces alcohol consumption in several rodent models (Leggio et al., 2011) . As NPY and CRF show overlapping expression patterns in the extended amygdala and opposing effects on anxiety and drinking, a concept has emerged that dysregulated NPY and CRF systems contribute to the motivation to seek alcohol in alcohol-dependent individuals (Valdez and Koob, 2004) . In this conceptualization, NPY acting at Y 1 receptors has anxiolytic properties that counteract pro-stress effects of CRF. In agreement with this idea, NPY acts as a functional antagonist of CRF effects on arousal and sleep (Ehlers et al., 1997) , and stress and anxiety (Britton et al., 2000; Sajdyk et al., 2006) , and opposes EtOH-stimulated, CRF-dependent GABA release in the CeA (Gilpin et al., 2011; Nie et al., 2004) . NPY also inhibits CRF neurons in the BNST via Y 1 receptors (Pleil et al., 2015) , and CRF and NPY produce opposing regulation of GABAergic transmission in this region (Kash and Winder, 2006) . Whether anxiolytic effects of NPY account for its ability to suppress drinking is uncertain given examples in which these 2 effects have been dissociated (Badia-Elder et al., 2003; Kallupi et al., 2014 ). However, current data support a role for NPY in limiting alcohol consumption and suggest that alterations in the balance between NPY and CRF signaling contribute to excessive alcohol consumption and increased anxiety in individuals with AUD. If indeed the case, then enhancing the function of Y 1 receptor signaling while inhibiting CRFR1 receptors may hold promise for reducing stress-induced alcohol craving and relapse in AUD.
CRF Actions at CRFR2
In contrast to Crhr1, Crhr2 mRNA expression in rats is more confined to subcortical structures and is most prominent in the lateral septum, posterior cortical amygdala, interpeduncular nucleus, supraoptic and ventromedial hypothalamic nuclei, and choroid plexus, with more modest expression in the BNST, olfactory bulb, dorsal raphe nucleus, hippocampus, and entorhinal cortex Lovenberg et al., 1995; Van Pett et al., 2000) . CRFR2 binds CRF with lower affinity than CRFR1 and binds the 3 other CRF-related peptides UCN1, UCN2, and UCN3. The behavioral effects of CRFR2 on anxiety and stress responses are complex, but in the extended amygdala it generally serves an anxiolytic function in opposition to CRFR1 (Reul and Holsboer, 2002) , contributing to stress recovery (Bale and Vale, 2004; Lebow et al., 2012) . Thus, in rats, reduced Crhr2 expression has been linked to PTSD-like behaviors (Elharrar et al., 2013 ) and a CRFR2 antagonist infused into the BNST increased anxiety-like behavior on the elevated plus maze (Tran et al., 2014) , although it also decreased acoustic startle (Tran et al., 2014) . By contrast, stimulation of CRFR2 receptors in the lateral septum of rats (Bakshi et al., 2007) and mice (Henry et al., 2006) , or activation of CRFR2-expressing neurons in the mouse lateral septum (Anthony et al., 2014) was anxiogenic.
Activation of CRFR2 typically reduces alcohol consumption in rodents. In C57BL/6J mice, intraventricular administration of the CRFR2 agonist UCN3 reduced drinking in DID (Lowery et al., 2010) and limited access, 2-bottle choice (Sharpe and Phillips, 2009) procedures, and in EtOH-dependent Wistar rats, intra-CeA administration of UCN3 reduced operant self-administration of alcohol . However, there were minimal differences in DID or continuous access, 2-bottle choice alcohol consumption between non-EtOH-dependent Crhr2 knockout and wild-type mice (Kaur et al., 2012; Sharpe et al., 2005) , and administration of the CRFR2 antagonist astressin-2B modestly reduced alcohol intake in C57BL/6J mice in the DID procedure (Albrechet-Souza et al., 2015) . As evidence suggests variation in CRFR2 expression levels in different affective states (Lebow et al., 2012) , future studies should focus on how CRFR2 levels change in the dependent state and whether its ability to counteract CRFR1 becomes compromised in alcohol dependence.
Additional Complicating Factors of the CRF System
Three additional factors regarding the CRF system bear discussion. The first is that, as mentioned earlier, CRFRs respond to multiple neuropeptides in vivo. CRFR1, for example, can also be activated by UCN1 (Henckens et al., 2016) , a peptide also implicated in alcohol intake (Giardino et al., 2017) . Because it is likely that endogenous CRF and UCN1 release are controlled differently, CRFR1 may be recruited by these endogenous ligands in distinct circuits for different ends. This situation raises the possibility that CRFR1 antagonists might produce conflicting outcomes, for example as already observed with opposing effects on fearversus state-dependent anxiety, as mentioned above. Second, particularly relative to other G protein-coupled receptors, there is a relative dearth of understanding of the molecular pharmacology of CRFRs, in terms of their signaling systems in vivo, their regulation by binding partners, and their potential direct regulation by alcohol. While the receptors are often described as Gs-linked G protein-coupled receptors, evidence suggests the possibility of coupling to multiple G protein-signaling systems (Henckens et al., 2016) . Third, most studies in animals have not examined the effects of chronic suppression of CRFR1 function. In fact, the first study that used gene targeted animals to examine the effect of CRFR1 on alcohol consumption reported no difference in continuous 2-bottle choice EtOH consumption between CRFR1 knockout and wild type until mice were subjected to repeated social defeat and swim stress, after which knockout mice persistently drank more EtOH than wild-type mice (Sillaber et al., 2002) . This result suggests caution about a potential interaction between chronic CRFR1 blockade and repeated stress, although because this study was carried out with a constitutive knockout mouse line, the results could have been due to developmental changes that would not be present in adult animals dosed repeatedly with CRFR1 antagonists.
SUMMARY AND CONCLUSIONS
During our literature review, we became aware of several issues that might have contributed to the failure of the recent CRFR1 antagonist trials in AUD. With regard to the pexacerfont trial, the complete lack of drug effect together with kinetic measurements of receptor engagement led us to conclude that it is difficult to make conclusions about whether CRFR1 is a drug target for AUD from the results of this trial. By contrast, drug target engagement was clearly demonstrated with verucerfont, but some issues with study design may have reduced chances for detecting a drug effect. These include the use of an inpatient hospital setting where subjects are removed from the stresses of personal life, the lack of male subjects in that study, and the use of alcohol cues when prior animal studies showed no effect of CRFR1 antagonism on alcohol-or cue-induced reinstatement. Also subjects in these studies were administered CRFR1 antagonists after inpatient detoxification, when the acute phase of withdrawal had past, in contrast to evidence from animal studies indicating that CRFR1 antagonism is effective in reducing drinking during early withdrawal. Perhaps a different trial design in which outpatient subjects are asked to abstain from alcohol for 2 to 3 days prior to a laboratory testing, and are subjected to stressors independent of alcohol cues, would be more likely to demonstrate a drug effect on craving (Fig. 1) . Additionally, a trial of verucerfont effect on alcohol drinking in subjects with AUD would be particularly useful. A negative result in such a trial would help validate the negative results using the stress-induced reinstatement of craving paradigm in the verucerfont laboratory study.
The decline in psychiatric drug discovery by major pharmaceutical companies stems in part from difficulties in translating results from animal models to humans (Hyman, 2012) . However, there is considerable support for using animal models to evaluate medications that may be effective in AUD (Egli, 2005) , and, as noted above, there are many drugs found to reduce drinking in animals that also reduce drinking in humans. However, for a specific drug target like CRFR1, there may be species differences in expression, signaling, or circuitry that diminish the ability of animal models to predict drug effects in humans. As discussed above, there are several interspecies differences in CRFR1 expression and virtually nothing is known about interspecies differences in CRFR1 signaling. Therefore, it is possible that species differences for CRFR1 present a formidable barrier to translation. Comparative studies of CRFR1 expression and signaling in rodents versus primates could enlighten this potentially important problem.
Another translational barrier to consider is that drugs against specific molecular targets may only work in certain individuals predisposed to respond. Thus, subjects who displayed high levels of state anxiety were specifically recruited to the pexacerfont and verucerfont trials with the assumption that they would be most likely to benefit, yet preclinical studies indicate that pathological amygdalar circuit adaptations due to stress are the result of latent traits that do not correlate with basal affective state (Bluett et al., 2017) . Another approach is to use genetic information to choose subjects with genomic variants that alter the function of the primary drug target (Fig. 1) . Pharmacogenetic approaches have only recently been applied to AUD medications development, first for naltrexone response and the A118G variant in the mu opioid receptor gene OPRM1 (Anton et al., 2008; Oslin et al., 2003; Ray et al., 2012) , and subsequently for ondansetron treatment and polymorphisms in the serotonin transporter gene 5-HTT (Johnson et al., 2011) and 5HT 3 receptor subunit genes , and more recently for topiramate and variants in the kainate receptor GRIK1 gene (Kranzler et al., 2014) . Given that several studies noted above have identified associations between single-nucleotide polymorphisms in the CRHR1 gene and AUD, a pharmacogenetics approach to patient selection in CRFR1 antagonist trials might be warranted. However, given the complex genetics of AUD, candidate gene approaches are likely to be of limited utility, and more systems based approaches that utilize transcriptional profiling, for example, may prove more effective (Warden et al., 2016) .
Along this line of reasoning, it is noteworthy that most drugs used in AUD, for which there are known mechanisms of action, interact with multiple protein targets. Examples include naltrexone, topiramate, and varenicline. Multiple target engagement may be advantageous for treating a complex multigenic disease like AUD. If true, then combination drugs that pair a CRFR1 antagonist with an agent that acts by a different mechanism, such as naltrexone, a KOR antagonist, a Y 1 receptor agonist, or a CRFR2 agonist, may prove more effective than drugs that are highly selective for a single target (Fig. 1) .
Given the high relapse rates with current AUD treatment and the role of stress in triggering relapse, it is important that efforts continue to discover drugs that reduce stress-induced relapse. However, until we have more data from ongoing clinical trials demonstrating an expected effect, or lack thereof, for drugs that reduce stress-evoked reinstatement in animals and craving in human laboratory trials, we would argue that it is premature to use negative results in the pexacerfont and verucerfont trials as cause to halt further testing of CRFR1 antagonists in AUD.
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